On September 13, Guangzhou Canton Biologics Technology Co., Ltd. (“Canton Biologics”) announced the completion of its Series C financing round, raising over RMB 300 million. The round was led by SDIC Venture Capital, with participation from Guangdong Technology Financial Group, Taipu Life Science Investment, and Qianyin Investment. The proceeds from this financing round will be used to advance the company’s new technology R&D, commercial production capacity expansion, and international business strategic initiatives.
Founded in Guangzhou in 2016, Canton Biologics focuses on the large‑molecule biologic CDMSO field, providing one‑stop end‑to‑end services from biologics CMC development to commercial manufacturing and global clinical supply. The company has grown rapidly from its initial bases in the Greater Bay Area to six R&D and manufacturing sites worldwide, including Shanghai and Germany. Canton Biologics has achieved remarkable success in high‑yield cell line construction, high‑level expression of complex proteins, and international manufacturing capabilities. Notably, the company has made significant technological breakthroughs in IgM expression platforms, host cell engineering, high‑density cell culture, novel formulations, and analytical methods. In addition, Canton Biologics has set a new record in service speed, completing development from DNA to CMC manufacturing in just seven months, playing a critical role in rapidly advancing client products to the clinic.
Dr. Shen Xiao, Founder and CEO of Canton Biologics, stated: “We are very grateful to the investors in this round for their high recognition of Canton Biologics’ technological capabilities and growth potential. Since our founding, we have upheld the values of ‘Reliable, Efficient, Innovative’ and the mission of ‘Empowering the Future with Biotechnology’ to accelerate the high‑quality R&D and market launch of new drugs. This financing will further accelerate our new technology R&D and international expansion, enabling us to continuously empower our partners and benefit more patients.”
SDIC Venture Capital, the lead investor in this round, commented: “As a critical part of the biopharmaceutical industry chain, CDMOs/CMOs play a key supporting role in innovative drug R&D and post‑launch manufacturing. We continue to focus on and invest in biopharmaceutical companies that address major national strategic needs and demonstrate outstanding technological capabilities and operational management expertise. As a flagship large‑molecule drug CDMO, Canton Biologics has built comprehensive R&D and manufacturing facilities in Guangdong, Shanghai, and Germany after years of development. The company has an excellent international team and extensive experience and strong technical expertise in licensed cell line types, preclinical CMC process development, commercial manufacturing, and clinical supply chain services. We are optimistic about Canton Biologics’ future development and international expansion, and we believe the company will provide clients with even better full‑chain solutions and continue to empower them.”
Guangdong Technology Financial Group, a follow‑on investor, said: “While China’s innovative drug industry faces short‑term pressure, the long‑term growth logic remains unchanged. As a leading large‑molecule biologic CDMSO company in the Guangdong‑Hong Kong‑Macao Greater Bay Area, Canton Biologics provides critical support for sustained innovation in the region’s biopharmaceutical industry. The team has deep industry experience, an international perspective, youthful energy, and strong entrepreneurial drive. Canton Biologics’ rapid growth holds significant strategic importance for advancing Guangdong’s R&D outsourcing service reinforcement initiative. We are optimistic about Canton Biologics strengthening its advantageous position in the Greater Bay Area based on its leading cell line development and technology platforms.”
Taipu Life Science Investment, another follow‑on investor, stated: “Biotechnology empowers the future. Canton Biologics possesses an excellent international perspective, a customer‑centric service philosophy, a capable and energetic management team, a highly innovative and efficient technical engineering team, solid technology industrialization capabilities, and a persistent entrepreneurial spirit. As a continuing investor, we believe the company will make significant contributions to the broader development of biotechnology‑related industries.”
About SDIC Venture Capital
SDIC Venture Capital was established in 2016 as a venture capital fund management company under State Development & Investment Group Co., Ltd. (SDIC). It was set up on a market‑oriented basis to implement the national innovation‑driven development strategy, deepen the comprehensive strategic partnership with the Ministry of Science and Technology, and accelerate the transfer and commercialization of national scientific and technological achievements. Through platforms such as the National Science and Technology Major Achievement Transformation Fund, the SDIC Beijing‑Tianjin‑Hebei Technology Achievement Transformation Fund, the SDIC Hi‑Tech (Shenzhen) Venture Capital Fund, the SDIC (Ningbo) Technology Achievement Transformation Fund, and the SDIC Greater Bay Area Technology Achievement Transformation Fund, SDIC Venture Capital focuses on technology commercialization, key sectors including advanced manufacturing, electronics, biopharmaceuticals, and materials/energy, and strategic regional development plans such as Beijing‑Tianjin‑Hebei, the Yangtze River Delta, and the Greater Bay Area. It continuously promotes breakthroughs in core technology innovation and builds a healthy technology commercialization investment ecosystem.
About Guangdong Technology Financial Group
Guangdong Technology Financial Group Co., Ltd. (“Guangdong Technology Financial Group”) is a state‑owned enterprise authorized for operation by the People’s Government of Guangdong Province. It is one of China’s earliest venture capital institutions and the first provincial‑level technology finance group, dedicated to building an important platform supporting scientific and technological innovation in Guangdong. In recent years, the group has focused on high‑quality development, striving to become a leader in venture capital investment, a promoter of strategic emerging industries, and a discoverer and creator of value at the intersection of technology and finance. As of the latest data, the group has a registered capital of RMB 10.6 billion, total assets of RMB 38.595 billion, and has established or participated in 161 funds with a total scale of nearly RMB 80 billion. It has provided investment and financing services to more than 2,000 technology enterprises and helped more than 180 companies go public.
About Taipu Life Science Investment
Taipu Life Science Investment is an industrial investment firm focused on the broader life sciences sector, active in early‑stage primary market investments and mature enterprise investments in the secondary market. The management team partners have previously served as fund managers for large domestic public equity funds specializing in healthcare. The core management team members come from major domestic investment institutions and well‑known pharmaceutical companies. The team has professional disciplinary backgrounds, many years of experience in specialized investment, extensive industry and financial resources, deep experience in industrial investment, and a profound understanding of the venture capital and securities markets.
